阅读说明：本技术 表没食子儿茶素没食子酸酯在制备治疗血管疾病药物中的用途 (Application of epigallocatechin gallate in preparing medicine for treating vascular diseases ) 是由 朱依谆 刘新华 龙芬 于瀛 于 2018-07-19 设计创作，主要内容包括：本发明属化合物药物用途技术领域,涉及表没食子儿茶素没食子酸酯(EGCG)在制备治疗血管内膜增生相关的血管疾病药物中的用途。本发明通过药理实验及体外与体内实验,建立小鼠颈动脉结扎内膜增生模型和PDGF-BB诱导VSMCs的体外细胞增殖与迁移模型,结果表明EGCG通过降低血管损伤后内膜增生的厚度,抑制血管组织细胞增殖相关蛋白的表达发挥对血管重构的治疗作用,所述EGCG通过抑制PDGF-BB诱导的大鼠原代平滑肌细胞增殖和迁移水平,降低VSMCs细胞增殖和迁移相关蛋白的表达对血管重构过程进行调控；进一步可用于制备防治血管内膜增生的药物。(The invention belongs to the technical field of compound medicine application, and relates to application of epigallocatechin gallate (EGCG) in preparation of a medicine for treating vascular intimal hyperplasia-related vascular diseases, wherein a mouse carotid artery ligation intimal hyperplasia model and a PDGF-BB induction VSMCs in-vitro cell proliferation and migration model are established through pharmacological experiments and in-vitro and in-vivo experiments, and results show that EGCG can be used for regulating and controlling a vascular remodeling process by reducing the intimal hyperplasia thickness after vascular injury and inhibiting the expression of vascular tissue cell proliferation-related proteins through inhibiting PDGF-BB induction primary rat smooth muscle cell proliferation and migration level and reducing the expression of VSMCs cell proliferation and migration-related proteins, and steps can be used for preparing the medicine for preventing and treating vascular intimal hyperplasia.)

1. The application of epigallocatechin gallate EGCG in preparing medicine for treating vascular diseases;

the molecular formula of the EGCG is as follows: C22H 18011.

2. The use according to claim 1, wherein said vascular disorder agent is a vascular disorder agent associated with intimal hyperplasia of the blood vessels.

3. Application of epigallocatechin gallate EGCG in preparing medicine for preventing and treating intimal hyperplasia after vascular injury is disclosed.

4. Use according to claim 1 or 3, wherein said EGCG acts to inhibit the effects of the expression of cell proliferation-related proteins in vascular tissue on vascular remodeling by reducing the thickness of intimal hyperplasia following vascular injury.

5. The use of claim 1 or 3, wherein said EGCG regulates vascular remodeling by inhibiting PDGF-BB-induced proliferation and migration levels in rat primary smooth muscle cells and by reducing VSMCs expression of cell proliferation and migration associated proteins.

Technical Field

The invention belongs to the technical field of compound medicine application, relates to a new application of epigallocatechin gallate (EGCG) in pharmacy, and particularly relates to an application of epigallocatechin gallate (EGCG) in preparation of a medicine for treating vascular diseases related to intimal hyperplasia of blood vessels.

Background

Disclosure of Invention

The invention aims to provide a new application of epigallocatechin gallate (EGCG) in pharmacy based on the basis of the prior art, and particularly relates to an application of epigallocatechin gallate (EGCG) in preparing a medicament for treating vascular diseases related to intimal hyperplasia of blood vessels.

The molecular formula of the epigallocatechin gallate (EGCG) is C22H18011, pharmacological experiments and in vitro and in vivo experiments show that the EGCG participates in the processes of cell proliferation and blood vessel reconstruction, has the effect of preventing and treating intimal hyperplasia after blood vessel injury, and can be used for preparing the medicament for preventing and treating the intimal hyperplasia in blood vessels in step

The invention adopts a C57BL/6J mouse carotid artery ligation injury model, and an HE staining method is adopted to detect the influence of EGCG on the intimal hyperplasia thickness of blood vessels; the results show that EGCG significantly reduced intimal hyperplasia thickness; the method comprises the steps of detecting the influence of EGCG on cell proliferation and migration activity by establishing a cell proliferation and migration model of primary Vascular Smooth Muscle Cells (VSMCs) of rats induced by platelet-derived growth factors (PDGF-BB) in vitro, and determining the change of cell proliferation level when the compound is used by an Edu method, wherein the result shows that the EGCG can obviously inhibit cell proliferation; the results of Transwell method detection show that the PDGF-BB-induced cell migration can be significantly inhibited; in addition, EGCG can inhibit the expression level of cell proliferation and migration related proteins Cyclin D1, Cyclin E, PCNA and MMP 9; experiments prove that the compound epigallocatechin gallate (EGCG) can inhibit the proliferation and migration process of primary vascular smooth muscle cells and has the function of treating vascular intimal hyperplasia.

The epigallocatechin gallate (EGCG) can be used for preparing a medicament for treating vascular diseases related to intimal hyperplasia of blood vessels.

Drawings

FIG. 1: the effect of EGCG on intimal hyperplasia thickness,

wherein, Sham: a sham operation group; injury: carotid artery ligation injury group; EGCG 5 mg: carotid artery ligation injury + EGCG administration group, 5 mg/kg/day; 10mg of EGCG: carotid artery ligation injury + EGCG administration group, 10 mg/kg/day; EGCG20 mg: carotid artery ligation injury + EGCG administration group, 20 mg/kg/day.

FIG. 2: the effect of EGCG on PDGF-BB induced proliferation levels of VSMCs,

wherein, Control: normal control group, PDGF: model group, PDGF + EGCG: EGCG, 30. mu.M, ^ B: compared with a normal control group, the p of the model group is less than 0.05; *: the EGCG group was given p < 0.05 compared to the model group.

FIG. 3: the effect of EGCG on PDGF-BB induced cell migration levels of VSMCs,

wherein, Control: normal control group, PDGF: model group, PDGF + EGCG: EGCG, 30. mu.M, ^ B: compared with a normal control group, the model group has p less than O.05; *: the EGCG group was given p < O.05 compared to the model group.

FIG. 4: the influence of EGCG on PDGF-BB induced VSMCs cell proliferation and migration related protein expression level,

wherein, Control: normal control group, PDGF: model group, PDGF + EGCG: EGCG, 30. mu.M, ^ B: compared with a normal control group, the model group has p less than O.05; *: the EGCG group was given p < O.05 compared to the model group.

Detailed Description